Compare multi-agent consensus ratings, forecast paths, AI price targets, expected return, fundamentals, analyst disagreement, risks, and the investment thesis across short- and long-term horizons.

ROP.SIX

Roche Holding

Healthcare | Drug Manufacturers - General

Swiss multinational healthcare company pioneering pharmaceuticals and diagnostics with focus on oncology, immunology, and infectious diseases.

Flagship Insight

How Computational Biology Moats Are Quietly Reshaping Global Healthcare Valuations

There is high consensus that structural currency headwinds mask robust underlying volume growth. While legacy patent expirations present near-term friction, the integration of artificial intelligence into diagnostics and the clinical advancement of a next-generation metabolic pipeline establish a durable, self-funded compounding trajectory for long-term capital preservation.

Forecast TimelineUpdated On Jul 03 2026

Roche Holding (ROP) Stock Forecast and AI Rating

Recommendation

Small Buy

Open a small position; wait before adding more.

2027

1-Year

STRONG BUY

381 CHF

+11.8%

+14.4% IF INCL. DIVS

2029

3-Year

N/A

452 CHF

+35%

2031

5-Year

BUY

531 CHF

+56%

+79% IF INCL. DIVS

LATEST DEEP FORECAST ANALYSIS BY iPULSE AI ENGINE | Jul 05, 2026

Visionary, Superintelligence, Insider, Strategist, Value Seeker, Vulture, Whistleblower, and more.

Elon Musk (Visionary), Superintelligence (Anthropologist), Machiavelli (Insider), Ray Dalio (Strategist), Warren Buffett (Value Purist), Michael Burry (Vulture), Sherlock Holmes (Whistleblower).

Research support only. We don't give financial advice.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Grok

Investment Thesis Takeaway

Expert LanguageExpert Quant Language

Explained Simply

Interactive forecast chart

Expert Language

Explained Simply

The asset is actively transitioning from a legacy pharmaceutical model facing patent cliffs into a vertically integrated computational biology platform. While reported financials suffer from Swiss Franc translational drag, underlying constant-currency volume growth remains robust. The dual diagnostics-therapeutics engine generates massive free cash flow, insulating the company from high-rate macro regimes and self-funding its entry into the high-TAM metabolic market. This self-sustaining model allows the firm to bypass expensive debt markets and aggressively fund next-generation pipelines, positioning it as an adaptive beneficiary of technological disruption.

Key insights

AI-driven R&D compression structurally lowers drug discovery cycle times and clinical failure rates by utilizing massive proprietary datasets and advanced computational modeling.
The diagnostics division serves as an high-margin data chokepoint, driving personalized medicine synergies and securing customer lock-in across global hospital networks.
Clinical maturation of the metabolic pipeline provides a massive, unpriced call option on the global obesity market with superior tolerability profiles.
Structural currency mismatch remains a persistent accounting friction, masking underlying operational momentum and depressing reported headline growth in the base currency.
A fortress balance sheet with minimal leverage provides absolute downside protection and strategic M&A optionality during market dislocations and credit contractions.
Impending patent cliffs on legacy biologics require flawless execution of next-generation product launches to sustain long-term margins and offset biosimilar erosion.

Preparing your access...

AI Consensus

AI Opinions

Company Profile

Roche Holding quarterly forecast scenarios

One row per forecast quarter. Asset scenario targets are shown in CHF; benchmark values are shown in USD.

Quarterly Bear Case, Base Case, Bull Case, and S&P 500 benchmark forecasts for Roche Holding.
Quarter	Forecast date	Bear Case (CHF)	Base Case (CHF)	Bull Case (CHF)	S&P 500 benchmark (USD)
Quarter 1+3M	Oct 03, 2026	347.41 CHF	351.95 CHF	357.63 CHF	$736.09
Quarter 2+6M	Jan 03, 2027	357.83 CHF	363.39 CHF	371.94 CHF	$724.14
Quarter 3+9M	Apr 03, 2027	357.55 CHF	367.93 CHF	386.81 CHF	$713.57
Quarter 4+1Y	Jul 03, 2027	361.31 CHF	373.10 CHF	394.55 CHF	$723.38
Quarter 5+15M	Oct 03, 2027	354.08 CHF	380.94 CHF	414.28 CHF	$716.61
Quarter 6+18M	Jan 03, 2028	350.54 CHF	393.10 CHF	426.70 CHF	$738.34
Quarter 7+21M	Apr 03, 2028	357.55 CHF	397.56 CHF	422.88 CHF	$746.91
Quarter 8+2Y	Jul 03, 2028	350.40 CHF	403.50 CHF	434.90 CHF	$771.93
Quarter 9+27M	Oct 03, 2028	364.42 CHF	413.86 CHF	447.94 CHF	$782.73
Quarter 10+30M	Jan 03, 2029	378.99 CHF	428.40 CHF	474.82 CHF	$807.31
Quarter 11+33M	Apr 03, 2029	390.36 CHF	432.25 CHF	484.32 CHF	$822.72
Quarter 12+3Y	Jul 03, 2029	402.07 CHF	441.18 CHF	498.85 CHF	$846.10
Quarter 13+39M	Oct 03, 2029	410.11 CHF	451.91 CHF	518.80 CHF	$852.53
Quarter 14+42M	Jan 03, 2030	422.42 CHF	463.65 CHF	503.24 CHF	$882.91
Quarter 15+45M	Apr 03, 2030	426.47 CHF	472.26 CHF	528.40 CHF	$900.46
Quarter 16+4Y	Jul 03, 2030	439.27 CHF	483.72 CHF	544.25 CHF	$922.67
Quarter 17+51M	Oct 03, 2030	448.05 CHF	493.54 CHF	566.02 CHF	$935.91
Quarter 18+54M	Jan 03, 2031	457.07 CHF	507.90 CHF	577.34 CHF	$952.30
Quarter 19+57M	Apr 03, 2031	461.49 CHF	519.13 CHF	600.43 CHF	$976.28
Quarter 20+5Y	Jul 03, 2031	470.87 CHF	531.36 CHF	618.45 CHF	$1,002

Alpha Gap and Advisor Disagreement

Alpha Gap

The core information gap lies in the market's systematic mispricing of the asset's structural evolution and its massive free cash flow yield. Wall Street treats the diagnostics and therapeutics divisions as separate, mature revenue streams, failing to recognize them as a closed-loop data engine. In the age of artificial intelligence, proprietary, high-fidelity clinical and genomic data is the most valuable asset, and this company sits at the chokepoint of this data topology. Furthermore, the crowd is pricing the obesity pipeline near zero due to a late-mover discount, ignoring clinical data that demonstrates best-in-class weight loss and tolerability. Investors are essentially acquiring a highly resilient, cash-gushing defensive asset at a liquidation-style discount while receiving a free, long-duration call option on a massive metabolic market.

Advisor Disagreement

The primary disagreements across the reports center on the timing and commercial viability of the metabolic pipeline. Some perspectives view the company as a late-mover that will struggle to capture meaningful market share from entrenched duopoly incumbents, while others argue that superior clinical profiles will allow it to easily secure a highly profitable fast-follower position. Additionally, there is minor divergence regarding the severity of the upcoming patent cliffs, with some models predicting significant near-term revenue erosion and others emphasizing the defensive capabilities of subcutaneous formulations and diagnostics integration.

Financial Reviews by iPulse AI

Earnings and financials

The company's financial health is incredibly strong, characterized by massive cash generation and a major rebound in net income, which jumped over fifty percent recently. While reported sales numbers look slightly down due to the strong Swiss currency, the actual volume of business is growing steadily at around six to seven percent. Analysts agree that the company's core business is highly profitable, but they disagree on how quickly new products can replace older ones facing patent expirations. Some expect a temporary dip in profits as research spending increases for new weight-loss trials, while others believe the rapid launch of new eye and cancer treatments will easily keep earnings growing. Overall, the company's ability to generate billions in free cash flow provides a massive safety net for investors.

Profitability and margins

The company boasts elite profitability, with gross margins holding steady at an impressive seventy-four percent and operating margins exceeding thirty percent. This reflects incredible pricing power and deep competitive advantages. Analysts agree that these high margins are protected by the company's unique medical testing division, which provides a stable, recurring floor for profits. However, there is some disagreement regarding the near-term margin trajectory. Some analysts expect slight margin compression due to the high costs of launching new weight-loss trials and government pricing pressures in the United States. Others believe that artificial intelligence efficiencies in research and high-margin software revenues will easily offset these pressures. Despite these minor clashes, the company's overall profitability remains far superior to most global competitors.

Balance sheet and leverage

The company's balance sheet is described as an impenetrable fortress, offering ultimate safety for investors. With a highly manageable debt-to-equity ratio and massive cash reserves, the company is completely insulated from rising interest rates and credit market volatility. Analysts universally agree that this financial strength provides a powerful shield against economic downturns. It also gives management the unique ability to execute strategic acquisitions of smaller, cash-starved biotech companies at deep discounts. There is virtually no disagreement on the safety of the balance sheet; it ensures the company can easily maintain its long history of dividend increases while continuing to fund its massive research programs. This financial safety makes the stock a premier defensive asset.

Capex and investment intensity

The company is highly disciplined with its physical spending, keeping traditional capital expenditures low at around six percent of sales. Instead, the real investment focus is on its massive research and development budget, which exceeds thirteen billion Swiss Francs annually. This heavy spending is shifting away from traditional laboratory work toward advanced artificial intelligence, supercomputing, and strategic acquisitions of promising biotech firms. Analysts agree that this high-tech shift will speed up drug discovery and make research much more efficient. However, there is some disagreement on the near-term cost of running massive clinical trials for new weight-loss drugs, which could temporarily weigh on cash flows. Ultimately, the company's ability to self-fund this massive innovation engine without taking on debt is a major competitive advantage.